<DOC>
	<DOCNO>NCT00087802</DOCNO>
	<brief_summary>The purpose study compare combination treatment gemcitabine + oxaliplatin ( GEMOX ) carboplatin + paclitaxel ( CP ) determine difference response safety two drug combination treatment advance non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Gemcitabine/Oxaliplatin ( GEMOX ) v Carboplatin/Paclitaxel ( CP ) Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Newly diagnose , Stage IIIb IV NSCLC , chemo systemic therapy naive One ( 1 ) unidimensionally measurable lesion ECOG Performance Status 0 1 , peripheral neuropathy &gt; Grade 1 Patients clinically stable brain metastasis stable dose ( longer require ) dexamethasone registration eligible . Patients receive cranial radiation brain metastasis must least 4 week last radiation treatment . Recovery full previous surgical procedure No history acute cardiac CNS event within 6 month entry current clinical evidence congestive heart failure nonstable coronary artery disease Hypersensitivity 4 study drug Concurrent immunotherapy participation investigational drug study within 4 week Serious uncontrolled intercurrent medical psychiatric illness organ allograft History malignancy within last 5 year ( except squamous basal cell carcinoma skin , carcinoma situ cervix , superficial transitional cell carcinoma bladder ) Patient pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>